Gilead Sciences, Inc.

Gilead Calistoga LLC

Carna Biosciences, Inc.

Leena Patel

Jennifer Anne Treiberg

Stephane Perreault

Suet Chung Yeung

Julian Andrew Codelli

Jayaraman Chandrasekhar

Yasamin Moazami

Gary Bruce Phillips

Kirk L Stevens

Kevin S Currie

Jerry B Evarts

Kassandra F Sedillo

Peter A Blomgren

Jeffrey E Kropf

Zhongdong Zhao

Musong Kim

Christopher T Clark

Jason K Perry

Taryn Campbell

Nicole Nava

Natalie Seeger

Devan Naduthambi

Tetsuya Kobayashi

Joshua J Van Veldhuizen

William John Watkins

Michael Graupe

Juan A Guerrero

Joshua A Kaplan

Jie Xu

Jesse M Jacobsen

Stephen D Holmbo

Heath A Weaver

Barton W Phillips

Jonathan William Medley

Qingming Zhu

Lafe J Purvis, Ii

Julian A Codelli

Suet C Yeung

Zhimin Du

Masaaki Sawa

Hirokazu Matsumoto

Arthur Yeung

Ryoko Nakai

Mai Arai

Nicholas Alexander Till

Seung H Lee

Jennifer Alissa Loyer-Drew

Patrick J Salvo

Shaopei Cai

Joshua I Kaplan

Eric Hu

Latesh Lad

Catherine Pugh

Jonah J Chang

David L Kukla

Thomas J Paul

Will Watkins

Gary Phillips

Jennifer A Treiberg

Joshua Van Veldhuizen

Joshua Kaplan

Jerry Evarts

Juan Guerrero

Stephen Holmbo

Jesse Jacobsen

Stephane Perrault

Lafe J Ii Purvis

Lafe J Purvis

Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.

PARP7 inhibitors

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

Diacylglycerol kinase modulating compounds

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

Quinoline derivatives

Diacylglyercol kinase modulating compounds

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.

Compounds for inhibition of &#x3b1;4 &#x3b2;7 integrin

Compounds for inhibition of alpha 4 beta 7 integrin

Compounds for inhibition of &#x3b1;4&#x3b2;7 integrin

Imidazopyridine derivatives

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A', B&#x2032;, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

Phosphatidylinositol 3-kinase inhibitors

The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein t, R, R, R, R, and Rare as described herein.

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein X, Y, Z, n, m', A&#x2032;, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

Growing community of inventors

Mercer Island, WA, United States of America

Leena Patel